IGC Pharma targets commercial rollout of PRISM layer for Alzheimer’s risk assessment and cognitive monitoring

Bitget2026/10/13 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IGC Pharma launched PRISM to move its Alzheimer’s AI from risk prediction into deployable clinical and consumer workflows.
Planning commercialization via B2B, B2B2C, online channels; targeting providers, memory clinics, drugmakers, trial sponsors, insurers.
PRISM slated to support earlier risk stratification, longitudinal cognitive monitoring, trial optimization, patient engagement for brain-health programs.
Strategy pairs PRISM with MINT-AD, while advancing AHA to speed Alzheimer’s dataset harmonization for research and clinical development.
CALMA Phase 2 trial of IGC-AD1 remains on track for topline results in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610130800ACCESSWRNAPR_____1236164) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IGC Pharma targets commercial rollout of PRISM layer for Alzheimer’s risk assessment and cognitive monitoring

You may also like

Crypto prices